Aqilion publishes Annual Report for 2022

AQILION AB (publ) hereby announces that the Swedish version of the 2022 Annual Report has been published.

The Annual Report, which is attached in Swedish, can also be downloaded from the company’s website. An English translation of the Annual Report will be available on the website no later than the week commencing May 22, 2023.

Sarah Fredriksson
CEO
sarah.fredriksson@aqilion.com

About Aqilion 
Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience in business development in innovative biotech and pharmaceutical companies, the company’s experienced team and Board of Directors have successfully navigated the process from drug discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com